ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner
Brain · 2025
DOI: 10.1093/brain/awaf463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Anna Steward und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Stroke and Dementia Research (ISD), University Hospital LMU, Munich 81377, Germany. Hauptthemen laut MEDLINE: tau Proteins, Apolipoprotein E4, Alzheimer Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Gefördert von: Bright Focus Foundation, Alzheimer's Association, Gerhard and Ilse Schick Foundation.
Abstract (Originalsprache)
In Alzheimer’s disease, carriage of the ApoE4 risk allele is linked to faster tau accumulation at lower amyloid-PET levels, thereby accelerating disease progression. However, it remains unclear whether this ApoE4-facilitated transition from amyloidosis to tauopathy is mechanistically promoted by increased secretion of phosphorylated (p)tau, a key intermediate that drives the amyloid-to-tauopathy transition, or alternatively by increased ptau-driven tau aggregation. Therefore, we investigated where along the amyloid-to-tau axis ApoE4 accelerates tau aggregation and assessed i) whether ApoE4 increases ptau secretion or ii) whether ApoE4 increases ptau-associated tau aggregation. To this end, we analysed two large-scale APOE-genotyped cohorts covering the full Alzheimer’s disease spectrum (ADNI: n=201) as well as a preclinical cohort (A4-LEARN: n=200), integrating baseline amyloid-PET, plasma ptau217 and CSF ptau181 with longitudinal tau-PET. Using linear regression, we tested whether ApoE4-carriage moderates i) amyloid-PET-associated plasma ptau217 increases or ii) ptau217-associated tau spreading from local epicentres across patient-tailored tau spreading stages. All analyses were independently validated across both cohorts, including an additional replication in an ADNI subset (n=115) with available CSF ptau181 measures as an alternative marker of ptau secretion. Finally, we used logistic regression to determine ApoE4 allele count-stratified plasma ptau217 thresholds marking early pathological tau-PET increases. We found that ApoE4 did not facilitate amyloid-PET-associated ptau increases, suggesting that amyloid-related ptau secretion is not altered by ApoE4-carriage. Contrastingly, we found that plasma ptau217 elevations were linked to faster tau-PET spread from local epicentres across connected brain regions in an ApoE4-allele dose-dependent manner, independent of amyloid (ADNI/A4-LEARN: mean β=0.44/0.56, p<0.001/<0.001). Lastly, we found that a higher ApoE4 allele count was linked to lower ptau217 thresholds marking transition to tauopathy, i.e. early abnormal tau-PET increases, consistently across both samples (ADNI: 0/1/2 ApoE4 alleles=0.62/0.34/0.15pg/ml, representing ∼45% and ∼76% reductions from non-carriers; Fujirebio ptau217 assay; A4/LEARN: 0/1/2 ApoE4 alleles=0.31/0.23/0.18pg/ml, representing ∼26% and ∼42% reductions; Eli Lilly ptau217 assay). These findings suggest that ApoE4, i.e. the key genetic risk factor for sporadic Alzheimer’s disease, facilitates amyloid-dependent tau aggregation in an allele dose-dependent manner by enhancing the ptau-driven spread of fibrillar tau, leading to an earlier transition from amyloidosis to tauopathy at lower ptau217 levels. This has implications for plasma ptau-based screening approaches and therapeutic timing of anti-amyloid drugs in ApoE4 carriers: Specifically, ApoE4 carriers may require genotype-adjusted ptau thresholds to detect Alzheimer’s disease pathophysiology, as well as anti-amyloid treatment at lower ptau levels to prevent the transition to tauopathy, which ultimately drives neurodegeneration and cognitive decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Stroke and Dementia Research (ISD), University Hospital LMU, Munich 81377, Germany.
- Department of Neurology, University Hospital LMU, Munich 81377, Germany.
- Max Planck School of Cognition, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig 04103, Germany.
- Department of Nuclear Medicine, University Hospital LMU, Munich 81377, Germany.
- Munich Cluster for Systems Neurology (SyNergy), Institute for Stroke and Dementia Research (ISD), Munich 81377, Germany.
- German Center for Neurodegenerative Diseases (DZNE) Munich, Institute for Stroke and Dementia Research (ISD), Munich 81377, Germany.
ORCID-Profile: Anna Dewenter, Sebastian N Roemer-Cassiano, Davina Biel, Lukas Frontzkowski, Carla Palleis, Martin Dichgans, Matthias Brendel, Nicolai Franzmeier
Förderung
- Bright Focus Foundation
- Alzheimer's Association
- Gerhard and Ilse Schick Foundation
Zitieren
APA
Steward, A., Dewenter, A., Hirsch, F., Roemer-Cassiano, S. N., Zhu, Z., Dehsarvi, A., Biel, D., Klonowski, M., Frontzkowski, L., Palleis, C., Gnörich, J., Dichgans, M., Höglinger, G., Brendel, M., & Franzmeier, N. (2025). ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner. Brain. https://doi.org/10.1093/brain/awaf463
Vancouver
Steward A, Dewenter A, Hirsch F, Roemer-Cassiano SN, Zhu Z, Dehsarvi A, et al. ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner. Brain. 2025. doi:10.1093/brain/awaf463
BibTeX
@article{Steward2025,
author = {Steward, Anna and Dewenter, Anna and Hirsch, Fabian and Roemer-Cassiano, Sebastian N and Zhu, Zeyu and Dehsarvi, Amir and Biel, Davina and Klonowski, Madleen and Frontzkowski, Lukas and Palleis, Carla and Gnörich, Johannes and Dichgans, Martin and Höglinger, Günter and Brendel, Matthias and Franzmeier, Nicolai},
title = {ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awaf463}
}
EUVIMED